Company: ZVRA
Filing Date: 2025-04-10
Form Type: PREC14A
Source: 0000897069-25-000784
Chunk: 12

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: PREC14A
Chunk 12
---
uring. Previously, Dr. Mickle served as President and Chief Executive Officer of Zevra from 2010 until 2023, where he led the company’s transition from a development-stage to a commercial-stage entity, securing multiple business partnerships and raising over $500 million in equity and debt financing. Dr. Mickle resigned as Chief Executive Officer of the Company effective January 6, 2023, and as President of the Company effective April 25, 2023. He also served as a director of the Company from its inception until the Company’s 2023 annual meeting of the stockholders. After his resignation as President of Zevra, Dr. Mickle served as a consultant for Zevra with respect to the development and approval of arimoclomol and other matters as requested until October 31, 2024. Mr. Travis C. Mickle, PhD, has over 25 years of pharmaceutical industry experience, including founding the Company, serving as President and Chief Executive Officer of Zevra from 2010 to 2023, and leading the development of multiple approved products. Earlier in his career, he was Lead Scientist at New River Pharmaceuticals, where he discovered and developed VYVANSE®, a multi-billion-dollar ADHD treatment. Dr. Mickle holds a PhD in Bio-Organic Chemistry from the University of Iowa and is named as an inventor on over 250 U.S. patents. His expertise spans drug discovery, regulatory strategy, corporate finance, and pharmaceutical commercialization. Dr. Mickle does not currently hold any position or office with the Company or any corporation or organization that is a parent, subsidiary, or affiliate of the Company. In concluding that Dr. Mickle should serve as a director of the Company, the Proponent considered his extensive experience within the pharmaceutical industry as well as his familiarity with the Company. Dr. Mickle’s past leadership of the Company and his experience with other pharmaceutical companies provide him with the qualifications and skills to serve as a director of the Company. For these reasons, the Proponent believes that Dr. Mickle should serve as a director of the Company. Arthur C. Regan, 62, serves as President & CEO of Regan & Associates, Inc. a New York, New York based proxy solicitation/shareholder services firm founded by him in 1991. From 1988 to 1991, Mr. Regan was the President of David Francis & 9 Co., Inc., a proxy solicitation firm. From 1984